Claus Henrik Nielsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1218010/publications.pdf

Version: 2024-02-01

122 papers 4,204 citations

94381 37 h-index 58 g-index

123 all docs

123 docs citations

times ranked

123

6463 citing authors

#	Article	IF	CITATIONS
1	Transcriptomic fingerprint of bacterial infection in lower extremity ulcers. Apmis, 2022, 130, 524-534.	0.9	8
2	Influence of Insulin Receptor Single Nucleotide Polymorphisms on Glycaemic Control and Formation of Anti-Insulin Antibodies in Diabetes Mellitus. International Journal of Molecular Sciences, 2022, 23, 6481.	1.8	4
3	Complement split product C3c in saliva as biomarker for periodontitis and response to periodontal treatment. Journal of Periodontal Research, 2021, 56, 27-33.	1.4	22
4	S100A11 (calgizzarin) is released via NETosis in rheumatoid arthritis (RA) and stimulates IL-6 and TNF secretion by neutrophils. Scientific Reports, 2021, 11, 6063.	1.6	17
5	CDX2 regulates interleukinâ€33 gene expression in intestinal epithelial cells (LS174T). FEBS Open Bio, 2021, 11, 1638-1644.	1.0	3
6	Elevated levels of oxidized nucleosides in individuals with the JAK2V617F mutation from a general population study. Redox Biology, 2021, 41, 101895.	3.9	8
7	Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. Scientific Reports, 2021, 11, 13153.	1.6	147
8	Identification of potential autoantigens in anti-CCP-positive and anti-CCP-negative rheumatoid arthritis using citrulline-specific protein arrays. Scientific Reports, 2021, 11, 17300.	1.6	5
9	Effectiveness of brodalumab after previous treatment failure of interleukin― <scp>17A</scp> inhibitors in patients with psoriasis. Dermatologic Therapy, 2021, 34, e15106.	0.8	7
10	Calibrationâ€"free concentration analysis for quantification of anti-drug specific antibodies in polyclonal positive control antibodies and in clinical samples. Journal of Immunological Methods, 2021, 497, 113002.	0.6	2
11	PADI4 Polymorphisms Confer Risk of Anti-CCP-Positive Rheumatoid Arthritis in Synergy With HLA-DRB1*04 and Smoking. Frontiers in Immunology, 2021, 12, 707690.	2.2	10
12	Applicability of Small-Molecule Inhibitors in the Study of Peptidyl Arginine Deiminase 2 (PAD2) and PAD4. Frontiers in Immunology, 2021, 12, 716250.	2.2	16
13	Insulinâ€like growth factor 1 and insulinâ€like growth factor binding proteinâ€3: impact on early haematopoietic reconstitution following allogeneic haematopoietic stem cell transplantation. European Journal of Haematology, 2021, , .	1.1	0
14	Citrullination of fibrinogen by peptidylarginine deiminase 2 impairs fibrin clot structure. Clinica Chimica Acta, 2020, 501, 6-11.	0.5	24
15	The Extracellular Polysaccharide Matrix of Pseudomonas aeruginosa Biofilms Is a Determinant of Polymorphonuclear Leukocyte Responses. Infection and Immunity, 2020, 89, .	1.0	22
16	Protein array-based companion diagnostics in precision medicine. Expert Review of Molecular Diagnostics, 2020, 20, 1183-1198.	1.5	6
17	Identification of Novel Native Autoantigens in Rheumatoid Arthritis. Biomedicines, 2020, 8, 141.	1.4	18
18	Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. Haematologica, 2020, 105, 2262-2272.	1.7	67

#	Article	IF	Citations
19	Thyroid Peroxidase Antibodies and Prospective Live Birth Rate: A Cohort Study of Women with Recurrent Pregnancy Loss. Thyroid, 2019, 29, 1465-1474.	2.4	43
20	Bâ€cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferonâ€Î±2, or combination treatment. European Journal of Haematology, 2019, 103, 351-361.	1.1	6
21	Associations between serum and plasma brain-derived neurotrophic factor and influence of storage time and centrifugation strategy. Scientific Reports, 2019, 9, 9655.	1.6	103
22	Expanding the citrullinome of synovial fibrinogen from rheumatoid arthritis patients. Journal of Proteomics, 2019, 208, 103484.	1.2	16
23	Stimulation of Mononuclear Cells Through Toll-Like Receptor 9 Induces Release of Microvesicles Expressing Double-Stranded DNA and Galectin 3-Binding Protein in an Interferon-α-Dependent Manner. Frontiers in Immunology, 2019, 10, 2391.	2.2	5
24	<p>Release of active peptidylarginine deiminase into the circulation during acute inflammation induced by coronary artery bypass surgery</p> . Journal of Inflammation Research, 2019, Volume 12, 137-144.	1.6	9
25	Erythrocytes restrict microvesicleâ€induced production of reactive oxygen species by polymorphonuclear leukocytes. Apmis, 2019, 127, 538-542.	0.9	O
26	Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis. Leukemia and Lymphoma, 2019, 60, 2549-2557.	0.6	5
27	Statin treatment, oxidative stress and inflammation in a Danish population. Redox Biology, 2019, 21, 101088.	3.9	44
28	Assessment of Peptidylarginine Deiminase Activity by ELISA Using Human Fibrinogen as Substrate. Methods in Molecular Biology, 2019, 1901, 239-242.	0.4	1
29	Increased proportions of B cells with spontaneous production of interleukinâ€10 in <scp>HIV</scp> â€infected individuals are normalized during combination antiretroviral therapy: a longitudinal study. Apmis, 2018, 126, 143-151.	0.9	5
30	Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. Oncolmmunology, 2018, 7, e1424674.	2.1	43
31	Reconstitution of Th17, Tc17 and Treg cells after paediatric haematopoietic stem cell transplantation: Impact of interleukin-7. Immunobiology, 2018, 223, 220-226.	0.8	16
32	Effects of rituximab and dexamethasone on regulatory and proinflammatory Bâ€eell subsets in patients with primary immune thrombocytopenia. European Journal of Haematology, 2018, 100, 45-52.	1.1	12
33	Surfactant Protein D Deficiency Aggravates Cigarette Smoke-Induced Lung Inflammation by Upregulation of Ceramide Synthesis. Frontiers in Immunology, 2018, 9, 3013.	2.2	17
34	Relative efficiencies of peptidylarginine deiminase 2 and 4 in generating target sites for anti-citrullinated protein antibodies in fibrinogen, alpha-enolase and histone H3. PLoS ONE, 2018, 13, e0203214.	1.1	27
35	Safety and efficacy of combination therapy of interferonâ€Î±2 and ruxolitinib in polycythemia vera and myelofibrosis. Cancer Medicine, 2018, 7, 3571-3581.	1.3	38
36	Longâ€term effects of angiotensin II blockade with irbesartan on inflammatory markers in hemodialysis patients: A randomized double blind placebo controlled trial (SAFIR study). Hemodialysis International, 2017, 21, 47-62.	0.4	5

#	Article	IF	CITATIONS
37	Peptidylarginine deiminase 2 is required for tumor necrosis factor alpha-induced citrullination and arthritis, but not neutrophil extracellular trap formation. Journal of Autoimmunity, 2017, 80, 39-47.	3.0	87
38	Low pretreatment levels of myeloid-related protein-8/14 and C-reactive protein predict poor adherence to treatment with tumor necrosis factor inhibitors in juvenile idiopathic arthritis. Clinical Rheumatology, 2017, 36, 67-75.	1.0	6
39	Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis. Arthritis Research and Therapy, 2017, 19, 79.	1.6	35
40	Surface complement C3 fragments and cellular binding of microparticles in patients with SLE. Lupus Science and Medicine, 2017, 4, e000193.	1.1	18
41	Immunoglobulin G antibodies against <i>Porphyromonas gingivalis</i> or <i>Aggregatibacter actinomycetemcomitans</i> in cardiovascular disease and periodontitis. Journal of Oral Microbiology, 2017, 9, 1374154.	1.2	28
42	Reactive oxygen species inhibit catalytic activity of peptidylarginine deiminase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2017, 32, 1203-1208.	2.5	29
43	Comorbidity of periodontal disease: two sides of the same coin? An introduction for the clinician. Journal of Oral Microbiology, 2017, 9, 1332710.	1.2	127
44	Effect of thrombopoietin-receptor agonists on circulating cytokine and chemokine levels in patients with primary immune thrombocytopenia (ITP). Platelets, 2017, 28, 478-483.	1.1	10
45	Cholesterol crystals enhance TLR2- and TLR4-mediated pro-inflammatory cytokine responses of monocytes to the proatherogenic oral bacterium Porphyromonas gingivalis. PLoS ONE, 2017, 12, e0172773.	1.1	23
46	Microparticles from patients with systemic lupus erythematosus induce production of reactive oxygen species and degranulation of polymorphonuclear leukocytes. Arthritis Research and Therapy, 2017, 19, 230.	1.6	13
47	Recent advances in understanding autoimmune thyroid disease: the tallest tree in the forest of polyautoimmunity. F1000Research, 2017, 6, 1776.	0.8	87
48	Bioactive small molecules in commercially available cereal food: Benzoxazinoids. Journal of Food Composition and Analysis, 2017, 64, 213-222.	1.9	9
49	The flame retardant DE-71 (a mixture of polybrominated diphenyl ethers) inhibits human differentiated thyroid cell function in vitro. PLoS ONE, 2017, 12, e0179858.	1.1	18
50	Pseudomonas aeruginosa Microcolonies in Coronary Thrombi from Patients with ST-Segment Elevation Myocardial Infarction. PLoS ONE, 2016, 11, e0168771.	1.1	11
51	Increased levels of peptidylarginine deiminase 2 in synovial fluid from anti-CCP-positive rheumatoid arthritis patients: Association with disease activity and inflammatory markers. Rheumatology, 2016, 55, 918-927.	0.9	42
52	<i>Lactobacillus reuteri</i> supplements do not affect salivary IgA or cytokine levels in healthy subjects: A randomized, double-blind, placebo-controlled, cross-over trial. Acta Odontologica Scandinavica, 2016, 74, 399-404.	0.9	21
53	Lipoprotein cholesterol fractions are related to markers of inflammation in children and adolescents with juvenile idiopathic arthritis: a cross sectional study. Pediatric Rheumatology, 2016, 14, 61.	0.9	12
54	Reduced glutathione as a physiological co-activator in the activation of peptidylarginine deiminase. Arthritis Research and Therapy, $2016,18,102.$	1.6	50

#	Article	IF	CITATIONS
55	Myelin Basic Protein-Induced Production of Tumor Necrosis Factor-α and Interleukin-6, and Presentation of the Immunodominant Peptide MBP85-99 by B Cells from Patients with Relapsing-Remitting Multiple Sclerosis. PLoS ONE, 2016, 11, e0146971.	1.1	8
56	Phthalates Are Metabolised by Primary Thyroid Cell Cultures but Have Limited Influence on Selected Thyroid Cell Functions In Vitro. PLoS ONE, 2016, 11, e0151192.	1.1	11
57	Effects of the Commercial Flame Retardant Mixture DE-71 on Cytokine Production by Human Immune Cells. PLoS ONE, 2016, 11, e0154621.	1.1	14
58	Dietary exposure to benzoxazinoids enhances bacteriaâ€induced monokine responses by peripheral blood mononuclear cells. Molecular Nutrition and Food Research, 2015, 59, 2190-2198.	1.5	2
59	Endogenous Interferon-Î ² -Inducible Gene Expression and Interferon-Î ² -Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis. PLoS ONE, 2015, 10, e0118830.	1.1	18
60	Viable Bacteria Associated with Red Blood Cells and Plasma in Freshly Drawn Blood Donations. PLoS ONE, 2015, 10, e0120826.	1.1	100
61	Characterization of Regulatory B Cells in Graves' Disease and Hashimoto's Thyroiditis. PLoS ONE, 2015, 10, e0127949.	1.1	41
62	Influence of Phthalates on in vitro Innate and Adaptive Immune Responses. PLoS ONE, 2015, 10, e0131168.	1.1	38
63	Effect of Polarization on Airway Epithelial Conditioning of Monocyte-Derived Dendritic Cells. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 368-377.	1.4	8
64	Associations between gastrointestinal toxicity, micro RNA and cytokine production in patients undergoing myeloablative allogeneic stem cell transplantation. International Immunopharmacology, 2015, 25, 180-188.	1.7	28
65	Benzoxazinoids: Cereal phytochemicals with putative therapeutic and healthâ€protecting properties. Molecular Nutrition and Food Research, 2015, 59, 1324-1338.	1.5	71
66	Differentiation of salivary bacterial profiles of subjects with periodontitis and dental caries. Journal of Oral Microbiology, 2015, 7, 27429.	1.2	32
67	Role of a Novel Human Leukocyte Antigen-DQA1*01:02;DRB1*15:01 Mixed Isotype Heterodimer in the Pathogenesis of "Humanized―Multiple Sclerosis-like Disease. Journal of Biological Chemistry, 2015, 290, 15260-15278.	1.6	7
68	Influence of Phthalates on Cytokine Production in Monocytes and Macrophages: A Systematic Review of Experimental Trials. PLoS ONE, 2015, 10, e0120083.	1.1	35
69	Absence of Bacteria on Coronary Angioplasty Balloons from Unselected Patients: Results with Use of a High Sensitivity Polymerase Chain Reaction Assay. PLoS ONE, 2015, 10, e0145657.	1.1	3
70	Rapid eye movement-sleep is reduced in patients with acute uncomplicated diverticulitisâ€"an observational study. PeerJ, 2015, 3, e1146.	0.9	2
71	Smoking is associated with increased levels of extracellular peptidylarginine deiminase 2 (PAD2) in the lungs. Clinical and Experimental Rheumatology, 2015, 33, 405-8.	0.4	27
72	Uptake and Presentation of Myelin Basic Protein by Normal Human B Cells. PLoS ONE, 2014, 9, e113388.	1.1	19

#	Article	IF	CITATIONS
73	Demonstration of extracellular peptidylarginine deiminase (PAD) activity in synovial fluid of patients with rheumatoid arthritis using a novel assay for citrullination of fibrinogen. Arthritis Research and Therapy, 2014, 16, 498.	1.6	68
74	Bacterial profiles of saliva in relation to diet, lifestyle factors, and socioeconomic status. Journal of Oral Microbiology, 2014, 6, 23609.	1.2	114
75	Preoperative Methylprednisolone Enhances Recovery After Endovascular Aortic Repair. Annals of Surgery, 2014, 260, 540-549.	2.1	81
76	Differences in bacterial saliva profile between periodontitis patients and a control cohort. Journal of Clinical Periodontology, 2014, 41, 104-112.	2.3	89
77	Generation of monoclonal antibodies against peptidylarginine deiminase 2 (PAD2) and development of a PAD2-specific enzyme-linked immunosorbent assay. Journal of Immunological Methods, 2014, 405, 15-22.	0.6	10
78	Activated Platelets Enhance IL-10 Secretion and Reduce TNF- \hat{l}_{\pm} Secretion by Monocytes. Journal of Immunology, 2013, 191, 4059-4067.	0.4	104
79	Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia. Blood, 2013, 121, 1976-1981.	0.6	146
80	B-cell exposure to self-antigen induces IL-10 producing B cells as well as IL-6- and TNF-α-producing B-cell subsets in healthy humans. Clinical Immunology, 2012, 145, 1-10.	1.4	17
81	Immunoregulation by Naturally Occurring and Disease-Associated Autoantibodies. Advances in Experimental Medicine and Biology, 2012, 750, 116-132.	0.8	14
82	Does a causal relation between cardiovascular disease and periodontitis exist?. Microbes and Infection, 2012, 14, 411-418.	1.0	37
83	Inflammatory Markers and Clustered Cardiovascular Disease Risk Factors in Danish Adolescents. Hormone Research in Paediatrics, 2012, 78, 288-296.	0.8	28
84	Surfactant Protein D Deficiency in Mice Is Associated with Hyperphagia, Altered Fat Deposition, Insulin Resistance, and Increased Basal Endotoxemia. PLoS ONE, 2012, 7, e35066.	1.1	14
85	Triterpene Acids from Rose Hip Powder Inhibit Selfâ€antigen―and LPS―nduced Cytokine Production and CD4 ⁺ T"ll Proliferation in Human Mononuclear Cell Cultures. Phytotherapy Research, 2012, 26, 1142-1147.	2.8	10
86	The cellular cancer resistance of the <scp>SR</scp> / <scp>CR</scp> mouse. Apmis, 2012, 120, 974-987.	0.9	1
87	Variation in NOD2 Augments Th2- and Th17 Responses to Myelin Basic Protein in Multiple Sclerosis. PLoS ONE, 2011, 6, e20253.	1.1	12
88	Targeted biological therapies for Graves $\hat{a} \in \mathbb{N}$ disease and thyroid $\hat{a} \in \mathbb{N}$ associated ophthalmopathy. Focus on $\hat{a} \in \mathbb{N}$ depletion with Rituximab. Clinical Endocrinology, 2011, 74, 1-8.	1.2	46
89	Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production. Multiple Sclerosis Journal, 2011, 17, 567-577.	1.4	23
90	The Atherogenic Bacterium (i> Porphyromonas gingivalis (i> Evades Circulating Phagocytes by Adhering to Erythrocytes. Infection and Immunity, 2011, 79, 1559-1565.	1.0	41

#	Article	IF	CITATIONS
91	Cell Saver for On-pump Coronary Operations Reduces Systemic Inflammatory Markers: A Randomized Trial. Annals of Thoracic Surgery, 2010, 89, 1511-1517.	0.7	54
92	The selfâ€antigen, thyroglobulin, induces antigenâ€experienced CD4 ⁺ T cells from healthy donors to proliferate and promote production of the regulatory cytokine, interleukinâ€10, by monocytes. Immunology, 2010, 129, 291-299.	2.0	11
93	Enhancement of Natural Killer Cell Activity in Healthy Subjects by Immulina \hat{A}^{\otimes} , a < i > Spirulina < /i > Extract Enriched for Braun-Type Lipoproteins. Planta Medica, 2010, 76, 1802-1808.	0.7	44
94	Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clinical Immunology, 2009, 130, 252-258.	1.4	79
95	A role for autoantibodies in enhancement of pro-inflammatory cytokine responses to a self-antigen, thyroid peroxidase. Clinical Immunology, 2009, 133, 218-227.	1.4	40
96	Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: a role in regulating cytokine responses to MBP. Immunology, 2009, 128, e451-61.	2.0	55
97	Spontaneous complement activation on human B cells results in localized membrane depolarization and the clustering of complement receptor type 2 and C3 fragments. Immunology, 2009, 128, e661-9.	2.0	10
98	Decreased Interleukinâ€2 Responses to <i>Fusobacterium nucleatum</i> and <i>Porphyromonas gingivalis</i> in Generalized Aggressive Periodontitis. Journal of Periodontology, 2009, 80, 800-807.	1.7	15
99	Epitope recognition patterns of thyroid peroxidase autoantibodies in healthy individuals and patients with Hashimoto's thyroiditis*. Clinical Endocrinology, 2008, 69, 664-668.	1.2	24
100	T helper cell type 1 (Th1), Th2 and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology, 2008, 125, 161-169.	2.0	175
101	The effect of \hat{l}^2 -interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis. Clinical Immunology, 2008, 129, 80-89.	1.4	14
102	Enhancement of Human Adaptive Immune Responses by Administration of a High-Molecular-Weight Polysaccharide Extract from the Cyanobacterium <i>Arthrospira platensis</i> . Journal of Medicinal Food, 2008, 11, 313-322.	0.8	51
103	Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves' disease. Gut, 2008, 57, 714-715.	6.1	155
104	Application of New Therapies in Graves' Disease and Thyroid-Associated Ophthalmopathy: Animal Models and Translation to Human Clinical Trials. Thyroid, 2008, 18, 973-981.	2.4	23
105	B Lymphocyte Depletion with the Monoclonal Antibody Rituximab in Graves' Disease: A Controlled Pilot Study. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1769-1772.	1.8	133
106	B-cell depletion with rituximab in the treatment of autoimmune diseases. Expert Opinion on Biological Therapy, 2007, 7, 1061-1078.	1.4	46
107	Evidence of Intrathyroidal B-Lymphocyte Depletion after rituximab Therapy in a Patient with Graves' Disease. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 3762-3763.	1.8	34
108	The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. European Journal of Endocrinology, 2006, 154, 623-632.	1.9	71

#	Article	IF	CITATIONS
109	Increased plasma levels of IL-6 in bacteremic periodontis patients after scaling. Journal of Clinical Periodontology, 2006, 33, 724-729.	2.3	66
110	Self-Reactive CD4+ T Cells and B Cells in the Blood in Health and Autoimmune Disease: Increased Frequency of Thyroglobulin-Reactive Cells in Graves' Disease. Journal of Clinical Immunology, 2006, 26, 126-137.	2.0	12
111	Treatment-Resistant Severe, Active Graves' Ophthalmopathy Successfully Treated with B Lymphocyte Depletion. Thyroid, 2006, 16, 709-710.	2.4	110
112	The Role of Complement in Immune and Autoimmune Responses. Transfusion Medicine and Hemotherapy, 2005, 32, 68-82.	0.7	2
113	Regulation of B-Cell Activation by Complement Receptors and Fc Receptors. Transfusion Medicine and Hemotherapy, 2005, 32, 339-347.	0.7	3
114	The classical and alternative pathways of complement activation play distinct roles in spontaneous C3 fragment deposition and membrane attack complex (MAC) formation on human B lymphocytes. Immunology, 2004, 111, 86-90.	2.0	13
115	Autoantibodies in autoimmune thyroid disease promote immune complex formation with self antigens and increase B cell and CD4+ T cell proliferation in response to self antigens. European Journal of Immunology, 2004, 34, 263-272.	1.6	60
116	Complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) cooperate in the binding of hydrolyzed complement factor 3 (C3i) to human B lymphocytes. European Journal of Immunology, 2003, 33, 3311-3321.	1.6	11
117	The role of complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) in promoting C3 fragment deposition and membrane attack complex formation on normal peripheral human B cells. European Journal of Immunology, 2002, 32, 1359.	1.6	23
118	Complement's participation in acquired immunity. Journal of Leukocyte Biology, 2002, 72, 249-61.	1.5	43
119	CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes. Immunology, 2001, 104, 418-422.	2.0	16
120	Natural autoantibodies and complement promote the uptake of a self antigen, human thyroglobulin, by B cells and the proliferation of thyroglobulin-reactive CD4+ T cells in healthy individuals. European Journal of Immunology, 2001, 31, 2660-2668.	1.6	55
121	The roles of complement receptors type 1 (CR1, CD35) and type 3 (CR3, CD11b/CD18) in the regulation of the immune complex-elicited respiratory burst of polymorphonuclear leukocytes in whole blood. European Journal of Immunology, 1997, 27, 2914-2919.	1.6	24
122	Circulating Brodalumab Levels and Therapy Outcomes in Patients With Psoriasis Treated With Brodalumab. JAMA Dermatology, 0, , .	2.0	5